title: Hematology in 2010: New therapies and standard of care in oncology.
abstract: 2010 was not a year of survival breakthroughs in hematologic malignancies. However, in Hodgkin's disease and multiple myeloma new therapies emerged as the standard of care and nilotinib may be considered the treatment choice for newly diagnosed chronic myeloid leukemia.
authors.affiliation: Yale Cancer Center, Yale School of Medicine, FMP 117, 333 Cedar Street, New Haven, CT 06519, USA. vincent.devita@yale.edu
authors.forename: Vincent T
authors.initials: VT
authors.lastname: DeVita
authors.forename: George P
authors.initials: GP
authors.lastname: Canellos
mesh_terms: D019337:Hematologic Neoplasms / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D059039:Standard of Care; D013997:Time Factors